Organic photovoltaic (OPV) solar cells are a promising emerging technology for sustainable energy generation. In these cells, the absorbing layer consists of a repeated series of aromatic organic rings with a system of π delocalized electrons, a feature that allows these materials to absorb sunlight and facilitate electron transfer. In the present work, a new tetrameric molecule with high structural complexity, 4-phenyl-7-(5-(thiazol-2-yl) thien-2-yl)benzo[c][1,2,5]thiadiazole, was synthesized by a convergent pathway. The final step of the synthetic route was the Suzuki coupling of two new dimeric molecules, obtained from commercially available raw materials such as thiophene and o-phenylenediamine. The band gap of the final compound was found to be 2.5 eV using an optical methodology and 2.38 eV using an electrochemical methodology. The results suggest that this tetrameric molecule has potential for application in OPV cells.
Some new quinoline linked fused 1,2,3-triazole hybrids (5a-5o) were synthesized via Cu(I) catalyzed azide-alkyne cycloaddition followed by intramolecular CH arylation in one pot. Further, these derivatives were screened for their anti-breast cancer activity against MCF-7, MDA-MB-468 and MDA-MB-231 cell lines and results were compared with the 5-fluorouracil (5-FU). Out of all, compounds 5a, 5c, 5f, 5g and 5j displayed higher activity than the 5-FU against three cancer cell lines. Compound 5a was more effective in inhibiting both tyrosine kinase EGFR and HER2 enzymes than the Erlotinib and Lapatinib. Furthermore, compound 5j demonstrated greater potency than the Erlotinib against EGFR. Molecular docking studies revealed the important binding features of most potent compounds 5a, 5c, 5f, 5g and 5j with EGFR (PDB ID-4HJO) and HER2 (PDB ID-3RCD) and results were found to be supportive with corresponding IC50 data. Finally, in silico pharmacokinetic studies revealed that compounds 5a, 5c, 5f, 5g and 5j followed Ghose, Egan, Muegge, Lipinski and Veber rules without any deviation.